Showing results (101-110 of 226) with videos related to

Sort By:
Pageof 23
Life Sciences|July 20, 2002
Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirusBernhard Sperker, Thomas E Mürdter, Janne T Backman, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinideLauri I Kajosaari, Janne T Backman, Mikko Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|June 27, 2015
Drug-Related Inadvertent Deaths in a University Hospital--A Declining TrendOuti Lapatto-Reiniluoto, Laura Patinen, Mikko Niemi, et al.
British Journal of Clinical Pharmacology|August 29, 2006
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjectsJanne T Backman, Marjo J Karjalainen, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|March 18, 2004
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsMikko Niemi, Lauri I Kajosaari, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprololJari J Lilja, Janne T Backman, Jouko Laitila, et al.
European Journal of Clinical Pharmacology|August 22, 2000
Effect of fluconazole on plasma fluvastatin and pravastatin concentrationsT Kantola, J T Backman, M Niemi, et al.
European Journal of Clinical Pharmacology|November 9, 2001
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivoK Villikka, T Varis, J T Backman, et al.
British Journal of Clinical Pharmacology|July 27, 2005
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinideMikko Niemi, Janne T Backman, Laura Juntti-Patinen, et al.
Pageof 23